ArticleF1000Research2022
Development of liquid culture media mimicking the conditions of sinuses and lungs in cystic fibrosis and health.
Article in F1000Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 11 citations in OpenAlex.
- Innovation in antifungal therapy.EMBO molecular medicine · 2026Review
- The longitudinal expression ofMicrobiology (Reading, England) · 2026Article
- Essential role of cytochromeFrontiers in cellular and infection microbiology · 2026Article
- Proteomic characterization ofVirulence · 2025Article
- Strain-dependent contribution of the AcrAB-TolC efflux pump toMicrobiology (Reading, England) · 2025Article
- The impact of respiratory tract mimicking media on antifungal susceptibility testing.Antimicrobial agents and chemotherapy · 2025Article
- Effects of Elevated Glucose on Bacterial Respiratory Infections in Cystic Fibrosis and Chronic Airway Diseases.International journal of molecular sciences · 2025Review
- Influence of Amino Acids on Quorum Sensing-Related Pathways inMetabolites · 2025Article
- Toward essential oil stewardship: strain-resolved evaluation of thyme oil activity againstFrontiers in pharmacology · 2025Article
- What Is a Biofilm? Lessons Learned from Interactions with Immune Cells.International journal of molecular sciences · 2024Review
- Modeling Cystic Fibrosis Chronic Infection Using Engineered Mucus-like Hydrogels.ACS biomaterials science & engineering · 2024Article
- A new model of endotracheal tube biofilm identifies combinations of matrix-degrading enzymes and antimicrobials able to eradicate biofilms of pathogens that cause ventilator-associated pneumonia.Microbiology (Reading, England) · 2024Article
- How Does Airway Surface Liquid Composition Vary in Different Pulmonary Diseases, and How Can We Use This Knowledge to Model Microbial Infections?Microorganisms · 2024Review
- Experimentally evolvedMicrobiology (Reading, England) · 2024Article
- Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo.Nature communications · 2024Article
- Secondary messenger signalling influences Pseudomonas aeruginosa adaptation to sinus and lung environments.The ISME journal · 2024Article
- Diverse regulatory pathways modulate bet hedging of competence induction in epigenetically-differentiated phase variants of Streptococcus pneumoniae.Nucleic acids research · 2023Article
- Preclinical testing of antimicrobials for cystic fibrosis lung infections: current needs and future priorities.Microbiology (Reading, England) · 2023Article
- Development of liquid culture media mimicking the conditions of sinuses and lungs in cystic fibrosis and health.F1000Research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
The respiratory tract is a compartmentalised and heterogenous environment. The nasopharynx and sinuses of the upper airways have distinct properties from the lungs and these differences may shape bacterial adaptation and evolution. Upper airway niches act as early colonisation sites for respiratory bacterial pathogens, including those, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.